Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Polatuzumab Vedotin-Piiq in Diffuse Large B-Cell Lymphoma: NCT06530511 Clinical Landscape Report 2026
15 October 2026
NCT06530511 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VNX-101 in High grade B-cell lymphoma: NCT06533579 Clinical Landscape Report 2026
15 October 2026
NCT06533579 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fluzoparib in Triple Negative Breast Cancer: NCT06533384 Clinical Landscape Report 2026
15 October 2026
NCT06533384 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Breast Cancer: NCT06532812 Clinical Landscape Report 2026
15 October 2026
NCT06532812 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mirabegron in Squamous Cell Carcinoma of Head and Neck: NCT06534762 Clinical Landscape Report 2026
15 October 2026
NCT06534762 clinical landscape for Squamous Cell Carcinoma of Head and Neck: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Ibrutinib in Primary mediastinal large B-cell lymphoma recurrent: NCT06536049 Clinical Landscape Report 2026
15 October 2026
NCT06536049 clinical landscape for Primary mediastinal large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and dev…
9 min read
MOv18 IgE(King's College London) in Triple Negative Breast Cancer: NCT06547840 Clinical Landscape Report 2026
15 October 2026
NCT06547840 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gefapixant Citrate in Dysgeusia: NCT06542484 Clinical Landscape Report 2026
15 October 2026
NCT06542484 clinical landscape for Dysgeusia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Bone metastases: NCT06538896 Clinical Landscape Report 2026
15 October 2026
NCT06538896 clinical landscape for Bone metastases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Birelentinib in Diffuse large B-cell lymphoma recurrent: NCT06539195 Clinical Landscape Report 2026
15 October 2026
NCT06539195 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
PF-07826390 in MSS/pMMR/MSI-L Colorectal Carcinoma: NCT06546553 Clinical Landscape Report 2026
15 October 2026
NCT06546553 clinical landscape for MSS/pMMR/MSI-L Colorectal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
XB-010 in Hormone receptor positive breast cancer: NCT06545331 Clinical Landscape Report 2026
15 October 2026
NCT06545331 clinical landscape for Hormone receptor positive breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…